---
title: Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
nct_id: NCT00232232
overall_status: COMPLETED
phase: PHASE4
sponsor: Melbourne Health
study_type: INTERVENTIONAL
primary_condition: Atrial Fibrillation
countries: Australia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00232232.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00232232"
ct_last_update_post_date: 2015-05-12
last_seen_at: "2026-05-12T07:24:54.484Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia

**NCT ID:** [NCT00232232](https://clinicaltrials.gov/study/NCT00232232)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Melbourne Health
- **Conditions:** Atrial Fibrillation, Atrial Flutter
- **Start Date:** 2003-09
- **Completion Date:** 2013-11
- **CT.gov Last Update:** 2015-05-12

## Brief Summary

The purpose of this study is to investigate whether fish oils may be of benefit to patients with certain heart rhythm disturbances called atrial fibrillation and atrial flutter.

Atrial fibrillation and atrial flutter are two heart conditions that can be successfully treated in the hospital by an ablation (in the case of atrial flutter) or a cardioversion (in the case of atrial fibrillation). Ablation involves the application of high frequency energy waves to a particular spot in the heart. Cardioversion involves resetting the heart back to a normal rhythm with the use of an electric current.

Fish oil supplements may be of benefit to patients with heart problems. Recent evidence suggests that fish oils may benefit those with rhythm disturbances.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Chronic atrial flutter requiring radiofrequency ablation.
* Chronic atrial fibrillation requiring internal cardioversion.

Exclusion Criteria:

* Sinus rhythm.
* Pregnancy.
* Patients \> 80 years and \< 18 years of age
```

## Arms

- **Control** (NO_INTERVENTION) — No fish oil
- **Fish oil** (EXPERIMENTAL) — Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio

## Interventions

- **Fish oil** (DRUG)

## Primary Outcomes

- **The extent of left atrial stunning in fish oil group compared to control after reversion of atrial arrhythmias to sinus rhythm.** _(time frame: 18 months)_

## Locations (1)

- Royal Melbourne Hospital, Melbourne, Victoria, Australia

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.royal melbourne hospital|melbourne|victoria|australia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00232232.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00232232*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*